Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

FORMA Therapeutics, Cubist Pharmaceuticals partner to develop antibacterial drugs
February 2009
SHARING OPTIONS:

CAMBRIDGE, Mass.FORMA Therapeutics announced in January a deal with Cubist Pharmaceuticals Inc. to leverage FORMA's transformative chemistry platform to discover novel antibacterial compounds for development by Cubist. FORMA will receive an upfront payment, equity investment, payments for compounds delivered and research funding over the three-year collaboration term totaling up to $14 million and is eligible to receive up to an additional $54 million in milestones plus royalties on programs Cubist elects to move into development and commercialization. Steven Gilman, CSO/SVP of discovery and non-clinical development at Cubist, says the deal will allow the companies to address areas of  antibacterial drug resistance such as methicillin resistant Staphylococcus aureus (MRSA) and gram negative infections. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.